Taste Disorders and Their Relation to BMI, FFQ, and EORTC QLQ-BR23 in Breast Cancer Patients During Chemotherapy.

NCT04543175 | Completed

• 1 other identifier: DI/13/111/04/0249
• Study Type: observational
• Target: 106
• Locations: 1 country
• Sites: 1

Brief Summary

Taste disorders in cancer patients during chemotherapy could be consider as multifactorial disease, it is related with changes of food consumption. Approximately 36-69% of the patients under chemotherapy suffer oral toxicity or dysgeusia A prospective case- only observational study was conducted in patients of the Hospital General de México for two years. A self-reported taste survey was used, and patients scored their results in a Likert scale.

Conditions

Breast Cancer; Taste Disorders; Dysgeusia; Ageusia; Quality of Life

Outcome Measures

Primary Outcomes (1)

• Prevalence of taste disorders and perception of the four basic flavors

  to assess the prevalence of taste alterations perception of the four basic flavors (sweet, salty, bitter and acidic) in newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy

  21 days

Study Arms (1)

Chemotherapy breast cancer patients

Newly diagnosed breast cancer patients (clinical stages IA, IIA, IIB, IIIA and IIIB) before and after chemotherapy with the following drugs (Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel were followed until they complete four cycles of chemotherapy.

Other: Taste disorder´s test

Interventions

Taste disorder´s test OTHER

Each patient performed their own test placing three drops with a disposable dropper from each bottle into the center of the tongue for whole-mouth testing.

Also known as: Taste disorders

Chemotherapy breast cancer patients

Eligibility Criteria

• Age: 20 Years - 60 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients of Oncology ward in Hospital General de Mexico between 20 and 60 years old with newly diagnosed breast cancer. and chemotherapy with Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel.

You may qualify if:

• \- Chemotherapy with Doxorubicin + Cyclophosphamide (DC) or Paclitaxel + Carboplatin (PC) or Docetaxel.
• Exclusión Criteria:
• No smokers Infections in oral cavity Acute respiratory diseases Gastro- oesophageal reflux disease Other types of cancer.

Sponsors & Collaborators

• Hospital General de Mexico: lead

Study Sites (1)

Hospital General de México

Mexico City, 06726, Mexico

Location

MeSH Terms

Conditions

Breast Neoplasms; Taste Disorders; Dysgeusia; Ageusia

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Sensation Disorders; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: September 2, 2020
• First Posted: September 10, 2020
• Study Start: January 1, 2017
• Primary Completion: January 1, 2018
• Study Completion: January 1, 2019
• Last Updated: September 10, 2020

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will not share

Locations

ME (1)